http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010116530-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 |
| filingDate | 2008-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010116530-A |
| titleOfInvention | GALEN COMPOSITIONS OF ALISKIREN |
| abstract | 1. A solid oral dosage form obtained by rotational pressing, comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, the content of the active ingredient being more than 38 wt.% Based on the total weight of the oral dosage form, and the dosage form further comprises:! - a filler selected from microcrystalline cellulose, corn starch and / or calcium hydrogen phosphate, and! and crosslinked carboxymethyl cellulose as a disintegrant. ! 2. The solid oral dosage form according to claim 1, where the content of the active ingredient is more than 40 wt.%. ! 3. The solid oral dosage form according to claim 1, where the content of the active ingredient is in the range from 41 to 80 wt.%, For example from 41 to 60 wt.%. ! 4. The solid oral dosage form according to claim 1, where the content of the active ingredient is in the range from 41 to 60 wt.%. ! 5. The solid oral dosage form according to claim 1, wherein the active ingredient consists entirely of aliskiren or a pharmaceutically acceptable salt thereof, and its content is in the range of 75 to 300 mg of the free base in one unit dosage form. ! 6. The solid oral dosage form according to claim 1, wherein the aliskiren is in the form of half-fumarate and its content is 83 mg, 166 mg or 332 mg in one unit dosage form. ! 7. The solid oral dosage form according to claim 1, wherein the crosslinked carboxymethyl cellulose is preferably croscarmellose sodium. ! 8. The solid oral dosage form according to claim 1, where the excipient is present in an amount of from 3 to 45 wt.% Calculated |
| priorityDate | 2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.